Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18420784,T(max),"After a 100-mg single p.o. dose of [(14)C]dasatinib to healthy volunteers, the radioactivity was rapidly absorbed (T(max) approximately 0.5 h).",Metabolism and disposition of dasatinib after oral administration to humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420784/),h,0.5,567,DB01254,Dasatinib
<,18420784,elimination half-life,Both dasatinib and total radioactivity (TRA) plasma concentrations decreased rapidly with elimination half-life values of <4 h.,Metabolism and disposition of dasatinib after oral administration to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420784/),h,4,568,DB01254,Dasatinib
,24561338,flow rate,"Chromatographic separation of analytes was performed on YMC pack ODS AM (150mm×4.6mm, 5μm) column under gradient conditions with acetonitrile:2.0mM ammonium acetate buffer as the mobile phase at a flow rate of 1ml/min.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),[ml] / [min],1,3650,DB01254,Dasatinib
,24561338,extraction recovery,"Mean extraction recovery for ruxolitinib, nilotinib, and IS of 99.6%, 97.6% and 90.3% were consistent across low, medium, and high QC levels.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),%,99.6,3651,DB01254,Dasatinib
,24561338,extraction recovery,"Mean extraction recovery for ruxolitinib, nilotinib, and IS of 99.6%, 97.6% and 90.3% were consistent across low, medium, and high QC levels.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),%,97.6,3652,DB01254,Dasatinib
,24561338,extraction recovery,"Mean extraction recovery for ruxolitinib, nilotinib, and IS of 99.6%, 97.6% and 90.3% were consistent across low, medium, and high QC levels.",Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561338/),%,90.3,3653,DB01254,Dasatinib
,21903773,disease control rate,"Of 69 evaluable patients, three had confirmed partial responses and six had stable disease for 16 weeks or more (disease control rate = 13.0%); all nine of these tumors were HR+ (two were also HER2+).",A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903773/),%,13.0,6894,DB01254,Dasatinib
,34079220,m,Dasatinib and posaconazole were monitored in positive ion mode with the following mass transition pairs: m/z 488.2→401.1 for dasatinib and m/z 701.3→683.4 for posaconazole.,Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079220/),,488.2,6896,DB01254,Dasatinib
,34079220,m,Dasatinib and posaconazole were monitored in positive ion mode with the following mass transition pairs: m/z 488.2→401.1 for dasatinib and m/z 701.3→683.4 for posaconazole.,Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079220/),,701.3,6897,DB01254,Dasatinib
,34079220,limit of detection,"The established method expressed good linearity in 1-1000 ng/mL of dasatinib and 5-5000 ng/mL of posaconazole, with limit of detection was 1 ng/mL and 5 ng/mL, respectively.",Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079220/),[ng] / [ml],1,6898,DB01254,Dasatinib
,34079220,limit of detection,"The established method expressed good linearity in 1-1000 ng/mL of dasatinib and 5-5000 ng/mL of posaconazole, with limit of detection was 1 ng/mL and 5 ng/mL, respectively.",Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079220/),[ng] / [ml],5,6899,DB01254,Dasatinib
,23138519,flow rate,"The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×3 mm i.d., 4.6 µ) using methanol: 2 mM ammonium acetate buffer, pH 4.0 as mobile phase at a flow rate 1 mL/min in gradient mode.","Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138519/),[ml] / [min],1,7934,DB01254,Dasatinib
>,23138519,recoveries,The recoveries from spiked control samples were > 79% for all analytes and internal standard Intra- and Interday accuracy and precision of validated method were within the acceptable limits of < 15% at all concentration.,"Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138519/),%,79,7935,DB01254,Dasatinib
,22147077,dose,"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11921,DB01254,Dasatinib
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11922,DB01254,Dasatinib
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],3.51,11923,DB01254,Dasatinib
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,89,12771,DB01254,Dasatinib
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,83,12772,DB01254,Dasatinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,100,12901,DB01254,Dasatinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,14-39,12902,DB01254,Dasatinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,31,12903,DB01254,Dasatinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,50,12904,DB01254,Dasatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.5-2.5,12905,DB01254,Dasatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,2.0,12906,DB01254,Dasatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3,12907,DB01254,Dasatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.2-4.5,12908,DB01254,Dasatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,5.7-6.4,12909,DB01254,Dasatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3.0-4.5,12910,DB01254,Dasatinib
,23715577,time to reach maximum concentration,"Dasatinib pediatric pharmacokinetic parameters were comparable with those in adult studies, showing rapid absorption (time to reach maximum concentration, 0.5 to 6.0 hours) and elimination (mean half-life, 3.0 to 4.4 hours).",Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715577/),h,0.5 to 6.0,17096,DB01254,Dasatinib
,23715577,half-life,"Dasatinib pediatric pharmacokinetic parameters were comparable with those in adult studies, showing rapid absorption (time to reach maximum concentration, 0.5 to 6.0 hours) and elimination (mean half-life, 3.0 to 4.4 hours).",Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715577/),h,3.0 to 4.4,17097,DB01254,Dasatinib
,18500518,area under the plasma imatinib concentration versus time curve (AUC),"Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 microg/(mL h) alone versus 32.6 microg/(mL h) with antacid, P = 0.37; 80% power].",Effect of antacid on imatinib absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500518/),[μg] / [h·ml],31.7,27694,DB01254,Dasatinib
,18500518,area under the plasma imatinib concentration versus time curve (AUC),"Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 microg/(mL h) alone versus 32.6 microg/(mL h) with antacid, P = 0.37; 80% power].",Effect of antacid on imatinib absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500518/),[μg] / [h·ml],32.6,27695,DB01254,Dasatinib
,31008998,medication possession ratio,An extremely high medication adherence for dasatinib was observed; the median medication possession ratio was 99.4%.,Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31008998/),%,99.4,35765,DB01254,Dasatinib
,31008998,area under the concentration-time curve,"The receiver operating characteristic curve analysis revealed that the cutoff value for the dasatinib area under the concentration-time curve was 336.1 ng × h/mL (accuracy 88.9%, sensitivity 80.0%, specificity 100%, and receiver operating characteristic curve-area under the concentration-time curve 0.800) for achieving MMR within 6 months.",Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31008998/),[h·ng] / [ml],336.1,35766,DB01254,Dasatinib
surpassed,31008998,Cmin,These edematous adverse events developed after plasma dasatinib Cmin surpassed 3.0 ng/mL.,Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31008998/),[ng] / [ml],3.0,35767,DB01254,Dasatinib
,25540064,PFS,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,21,36679,DB01254,Dasatinib
,25540064,OS rates,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,43,36680,DB01254,Dasatinib
,32152879,plasma concentrations,"The plasma concentrations of dasatinib before, immediately, and 2 h after the completion of hemodialysis were 7.4, 6.1, and 59.5 ng/mL, respectively.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),,6.1,39573,DB01254,Dasatinib
,32152879,plasma concentrations,"The plasma concentrations of dasatinib before, immediately, and 2 h after the completion of hemodialysis were 7.4, 6.1, and 59.5 ng/mL, respectively.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),,59.5,39574,DB01254,Dasatinib
,32152879,trough concentration,"Because the patient's dasatinib trough concentration was higher (6.1 ng/mL) than the target level (1.5 ng/mL), we suspected the development of dasatinib-related heart dysfunction; thus, dasatinib was discontinued 6 months after its initiation.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),[ng] / [ml],6.1,39575,DB01254,Dasatinib
,32152879,trough concentration,"Because the patient's dasatinib trough concentration was higher (6.1 ng/mL) than the target level (1.5 ng/mL), we suspected the development of dasatinib-related heart dysfunction; thus, dasatinib was discontinued 6 months after its initiation.",Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152879/),[ng] / [ml],1.5,39576,DB01254,Dasatinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],17.2,50813,DB01254,Dasatinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],33.1,50814,DB01254,Dasatinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],27.7,50815,DB01254,Dasatinib
,22080802,flow rate,Chromatographic separation of the drugs is achieved on an RP-C(18) column at flow rate of 0.9 mL/min at 35°C; eluate is monitored at 267 nm.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ml] / [min],0.9,53637,DB01254,Dasatinib
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,40.24,53638,DB01254,Dasatinib
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,81.81,53639,DB01254,Dasatinib
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],10,53640,DB01254,Dasatinib
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53641,DB01254,Dasatinib
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53642,DB01254,Dasatinib
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],100,53643,DB01254,Dasatinib
,21523723,time to disease progression,"The median treatment duration was 59 days, the median time to disease progression was 3.9 weeks, and the median survival was 26 weeks.",Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21523723/),weeks,3.9,57608,DB01254,Dasatinib
,30838861,half-life,"Generally, the half-life for a drug to clear from a CED site is short for low molecular weight dasatinib analogs that bare different charge; 1-3 (1, 32.2 min (95% CI: 27.7-37.8), 2, 44.8 min (27.3-80.8), and 3, 71.7 min (48.6-127.6) minutes) and is much longer for a dasatinib-nanofiber conjugate, 5, (42.8-57.0 days).","Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30838861/),min,"1, 32.2",60359,DB01254,Dasatinib
,30838861,half-life,"Generally, the half-life for a drug to clear from a CED site is short for low molecular weight dasatinib analogs that bare different charge; 1-3 (1, 32.2 min (95% CI: 27.7-37.8), 2, 44.8 min (27.3-80.8), and 3, 71.7 min (48.6-127.6) minutes) and is much longer for a dasatinib-nanofiber conjugate, 5, (42.8-57.0 days).","Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30838861/),min,"2, 44.8",60360,DB01254,Dasatinib
,30838861,half-life,"Generally, the half-life for a drug to clear from a CED site is short for low molecular weight dasatinib analogs that bare different charge; 1-3 (1, 32.2 min (95% CI: 27.7-37.8), 2, 44.8 min (27.3-80.8), and 3, 71.7 min (48.6-127.6) minutes) and is much longer for a dasatinib-nanofiber conjugate, 5, (42.8-57.0 days).","Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30838861/),min,"3, 71.7",60361,DB01254,Dasatinib
,30838861,half-life,"Generally, the half-life for a drug to clear from a CED site is short for low molecular weight dasatinib analogs that bare different charge; 1-3 (1, 32.2 min (95% CI: 27.7-37.8), 2, 44.8 min (27.3-80.8), and 3, 71.7 min (48.6-127.6) minutes) and is much longer for a dasatinib-nanofiber conjugate, 5, (42.8-57.0 days).","Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30838861/),,5,60362,DB01254,Dasatinib
,25170013,MTD,MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),mg,150,73536,DB01254,Dasatinib
,25170013,MTD,MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),mg,70,73537,DB01254,Dasatinib
,25170013,overall disease control rate,The 35 NSCLC patients treated in phase II had an overall disease control rate of 59% at 6 weeks.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),%,59,73538,DB01254,Dasatinib
,25170013,PFS,Median PFS was 3.3 months.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),month,3.3,73539,DB01254,Dasatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],62,81997,DB01254,Dasatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],26,81998,DB01254,Dasatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],25,81999,DB01254,Dasatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],34,82000,DB01254,Dasatinib
,17429625,Percent distribution,Percent distribution in blood cells ranged from 43% in mouse to 57% in dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,43,82001,DB01254,Dasatinib
,17429625,Percent distribution,Percent distribution in blood cells ranged from 43% in mouse to 57% in dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,57,82002,DB01254,Dasatinib
>,17429625,volumes of distribution,Dasatinib showed high volumes of distribution (>3 l/kg) and high serum protein binding values (>90%) in all four species tested.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[l] / [kg],3,82003,DB01254,Dasatinib
>,17429625,serum protein binding,Dasatinib showed high volumes of distribution (>3 l/kg) and high serum protein binding values (>90%) in all four species tested.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,90,82004,DB01254,Dasatinib
,17429625,Oral bioavailability,Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,14,82005,DB01254,Dasatinib
,17429625,Oral bioavailability,Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,34,82006,DB01254,Dasatinib
,24409000,flow rate,"The mobile phase consisted of 20 mM ammonium formate (with 0.1 % formic acid): acetonitrile (70:30, v/v) pumped isocratically at a flow rate of 0.25 mL min-1 with a total run-time of 13 min.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),[ml] / [min],0.25,98557,DB01254,Dasatinib
,24409000,total run-time,"The mobile phase consisted of 20 mM ammonium formate (with 0.1 % formic acid): acetonitrile (70:30, v/v) pumped isocratically at a flow rate of 0.25 mL min-1 with a total run-time of 13 min.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),min,13,98558,DB01254,Dasatinib
,24409000,retention times,"The retention times of sunitinib and dasatinib were 7.8 and 5.5 min, respectively.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),min,7.8,98559,DB01254,Dasatinib
,24409000,retention times,"The retention times of sunitinib and dasatinib were 7.8 and 5.5 min, respectively.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),min,5.5,98560,DB01254,Dasatinib
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[h·μg] / [ml],34.1,102887,DB01254,Dasatinib
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[h·μg] / [ml],33.1,102888,DB01254,Dasatinib
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[μg] / [ml],2.04,102889,DB01254,Dasatinib
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[μg] / [ml],2.02,102890,DB01254,Dasatinib
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,13.4,102891,DB01254,Dasatinib
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,14.1,102892,DB01254,Dasatinib
,22407177,MTD,"The dasatinib MTD was 180 mg when combined with either 150 mg of erlotinib for patients not on EIAEDs, or 450 mg of erlotinib for patients on EIAEDs.",Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407177/),mg,180,105258,DB01254,Dasatinib
,32112275,time for maximal serum concentration,"Dasatinib is rapidly absorbed, with the time for maximal serum concentration varying between 0.25 and 1.5 h.",Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32112275/),h,0.25 and 1.5,115623,DB01254,Dasatinib
,32112275,terminal half-life,"Dasatinib is eliminated through cytochrome P450 (CYP) 3A4-mediated metabolism, with a terminal half-life of 3-4 h.",Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32112275/),h,3-4,115624,DB01254,Dasatinib
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[μg] / [l],209.01,121364,DB01254,Dasatinib
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[μg] / [l],223.07,121365,DB01254,Dasatinib
,27995880,Tmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,1.1,121366,DB01254,Dasatinib
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.10,121367,DB01254,Dasatinib
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.39,121368,DB01254,Dasatinib
,27995880,AUC0-τ,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],646.65,121369,DB01254,Dasatinib
,27995880,AUC0-τ,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],695.84,121370,DB01254,Dasatinib
,27995880,AUC0-∝,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],668.11,121371,DB01254,Dasatinib
,27995880,AUC0-∝,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],712.42,121372,DB01254,Dasatinib
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.32,121373,DB01254,Dasatinib
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.68,121374,DB01254,Dasatinib
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],"4,309.2",121535,DB01254,Dasatinib
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],716.3,121536,DB01254,Dasatinib
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],86.8,121537,DB01254,Dasatinib
,25374410,area under the plasma concentration-time curve (AUC0-8),"The area under the plasma concentration-time curve (AUC0-8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration.",Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25374410/),[h·ng] / [ml],492.75,121538,DB01254,Dasatinib
,20108303,corrected QT (QTc),"Coadministration of ketoconazole led to a marked increase in dasatinib exposure, which was correlated with an increase in corrected QT (QTc) values of approximately 6 msec.",Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108303/),,6,140551,DB01254,Dasatinib
,24113234,flow rate,"Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase of 0.02M potassium dihydrogen phosphate:methanol (10:90, v/v) pumped at flow rate of 2.0mL/min.",High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24113234/),[ml] / [min],2.0,150387,DB01254,Dasatinib
,22837181,PFS,"The median PFS and OS were 7.8 and 16.2 months, respectively.","A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837181/),month,7.8,169114,DB01254,Dasatinib
,22837181,PFS,"The median PFS and OS were 7.8 and 16.2 months, respectively.","A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837181/),month,16.2,169115,DB01254,Dasatinib
,22837181,OS,"The median PFS and OS were 7.8 and 16.2 months, respectively.","A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837181/),month,16.2,169116,DB01254,Dasatinib
,23090987,progression-free survival (PFS),Median progression-free survival (PFS) was 1.35 months (95% confidence interval: 1.2-1.4) and 6-month PFS was 7.7%.,EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090987/),month,1.35,192003,DB01254,Dasatinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],89.2,200125,DB01254,Dasatinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],141.1,200126,DB01254,Dasatinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200127,DB01254,Dasatinib
,33214787,maximum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200128,DB01254,Dasatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],16.7,200129,DB01254,Dasatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],141.1,200130,DB01254,Dasatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200131,DB01254,Dasatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[h·ng] / [ml],1278.5,200132,DB01254,Dasatinib
,33214787,area under the plasma concentration-time curve,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[h·ng] / [ml],1017.4,200133,DB01254,Dasatinib
,33214787,area under the plasma concentration-time curve,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ng·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ng·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[h·ng] / [ml],1278.5,200134,DB01254,Dasatinib
,22028489,OR,"ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively.",Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028489/),,4,205951,DB01254,Dasatinib
,22028489,PFS,Median PFS was 8.3 weeks (95% CI: 7.3-15.3).,Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028489/),weeks,8.3,205952,DB01254,Dasatinib
,26795401,run time,"The chromatography run time was 6min using an Agilent RRHD SB-C18 column with a gradient of acetonitrile and water (0.1% formic acid, v/v).",Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795401/),min,6,209491,DB01254,Dasatinib
,26795401,extraction recoveries,The extraction recoveries were in the range of 86-105% and no significant matrix effect was observed.,Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795401/),%,86-105,209492,DB01254,Dasatinib
,31676669,area under the concentration-time curve at steady state,"The area under the concentration-time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70-1.06].",Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31676669/),[ng] / [h·ml],"14,751.4",221031,DB01254,Dasatinib
,31676669,area under the concentration-time curve at steady state,"The area under the concentration-time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70-1.06].",Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31676669/),[ng] / [h·ml],"17,102.9",221032,DB01254,Dasatinib
,30535536,2 h,"Average (median, standard deviation, range) 2 h plasma concentration of drug was 119 (121, 80, 226) and 236 (162, 248, 633) ng/mL, for the 100 and 200 mg DL, respectively.",A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30535536/),[ng] / [ml],119,224042,DB01254,Dasatinib
,30535536,plasma concentration of drug,"Average (median, standard deviation, range) 2 h plasma concentration of drug was 119 (121, 80, 226) and 236 (162, 248, 633) ng/mL, for the 100 and 200 mg DL, respectively.",A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30535536/),[ng] / [ml],119,224043,DB01254,Dasatinib
,30535536,plasma concentration of drug,"Average (median, standard deviation, range) 2 h plasma concentration of drug was 119 (121, 80, 226) and 236 (162, 248, 633) ng/mL, for the 100 and 200 mg DL, respectively.",A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30535536/),[ng] / [ml],236,224044,DB01254,Dasatinib
,23334925,absolute bioavailability,"Friend Leukemia Virus Strain B (FVB) mice were used to determine the bioavailability of elacridar after a 10 mg/kg dose of elacridar in the microemulsion, intraperitoneally (i.p.) and orally (p.o.); and the absolute bioavailability was determined to be 1.3 and 0.47, respectively.",Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334925/),,1.3,233430,DB01254,Dasatinib
,23334925,absolute bioavailability,"Friend Leukemia Virus Strain B (FVB) mice were used to determine the bioavailability of elacridar after a 10 mg/kg dose of elacridar in the microemulsion, intraperitoneally (i.p.) and orally (p.o.); and the absolute bioavailability was determined to be 1.3 and 0.47, respectively.",Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334925/),,0.47,233431,DB01254,Dasatinib
,23536435,MTD,The MTD of vandetanib and dasatinib in combination was 65 mg/m(2) for each drug.,"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23536435/),[mg] / [m(2],65,237227,DB01254,Dasatinib
,22678358,total area under the total plasma concentration-time curve (AUC(0-12)),"Here, we report a patient treated with dasatinib and H2RA famotidine for whom the total area under the total plasma concentration-time curve (AUC(0-12)) of dasatinib dramatically increased after cessation of famotidine from 505.7 to 1,816.3 ng·h/mL.",H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678358/),[h·ng] / [ml],505.7,244961,DB01254,Dasatinib
,22678358,total area under the total plasma concentration-time curve (AUC(0-12)),"Here, we report a patient treated with dasatinib and H2RA famotidine for whom the total area under the total plasma concentration-time curve (AUC(0-12)) of dasatinib dramatically increased after cessation of famotidine from 505.7 to 1,816.3 ng·h/mL.",H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678358/),[h·ng] / [ml],"1,816.3",244962,DB01254,Dasatinib
,34240339,area under the concentration-time curve extrapolated to steady state (AUCss),"The mean (standard deviation) of the estimated area under the concentration-time curve extrapolated to steady state (AUCss) of dasatinib 60 and 80 mg/m2 was 366.1 (146.6) ng·h/mL and 425.3 (150.7) ng·h/mL, respectively.",Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34240339/),[h·ng] / [ml],366.1,247612,DB01254,Dasatinib
,34240339,area under the concentration-time curve extrapolated to steady state (AUCss),"The mean (standard deviation) of the estimated area under the concentration-time curve extrapolated to steady state (AUCss) of dasatinib 60 and 80 mg/m2 was 366.1 (146.6) ng·h/mL and 425.3 (150.7) ng·h/mL, respectively.",Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34240339/),[h·ng] / [ml],425.3,247613,DB01254,Dasatinib
,29501533,survival,"Finally, the improved nanocarrier pharmacokinetics led to prolonged median survival of mice bearing a clinically relevant PDX model of alveolar rhabdomyosarcoma from 19 days for the untreated controls to 27 days for the targeted therapy.",Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501533/),,19,249290,DB01254,Dasatinib
,29404062,flow rate,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),[ml] / [min],0.25,256216,DB01254,Dasatinib
,29404062,total run time,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),min,6,256217,DB01254,Dasatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,494.5,256218,DB01254,Dasatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,394.5,256219,DB01254,Dasatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,488.7,256220,DB01254,Dasatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,530.7,256221,DB01254,Dasatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,289.5,256222,DB01254,Dasatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,528.5,256223,DB01254,Dasatinib
,29342447,IC50,The PTK assay provides promising activity at IC50 of 0.07 µM in the human breast cancer cell line MDA-MB-468.,"Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342447/),μM,0.07,256869,DB01254,Dasatinib
,29342447,oral bioavailability,It had 54.22% oral bioavailability with Tmax of 0.60 h which is higher compared to the dasatinib with bioavailability and Tmax of 14-34% and 1-1.42 h respectively.,"Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342447/),%,54.22,256870,DB01254,Dasatinib
,29342447,Tmax,It had 54.22% oral bioavailability with Tmax of 0.60 h which is higher compared to the dasatinib with bioavailability and Tmax of 14-34% and 1-1.42 h respectively.,"Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342447/),h,0.60,256871,DB01254,Dasatinib
,29342447,bioavailability,It had 54.22% oral bioavailability with Tmax of 0.60 h which is higher compared to the dasatinib with bioavailability and Tmax of 14-34% and 1-1.42 h respectively.,"Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342447/),%,14-34,256872,DB01254,Dasatinib
,29342447,Tmax,It had 54.22% oral bioavailability with Tmax of 0.60 h which is higher compared to the dasatinib with bioavailability and Tmax of 14-34% and 1-1.42 h respectively.,"Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342447/),h,1-1.42,256873,DB01254,Dasatinib
>,21982905,recoveries,Assay recoveries were high (>79%) and internal standard normalized matrix effects were minimal.,A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982905/),%,79,257622,DB01254,Dasatinib
,23980865,gastric pH,The average gastric pH in fasted dogs ranged from 1.45 to 3.03.,Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980865/),,1.45 to 3.03,265403,DB01254,Dasatinib
,22587422,C(2h),"The median plasma concentration at 2 hours (C(2h)), the median plasma maximum concentration (C(max)), and the median area under the observed plasma concentration-time curve from 0 to 4 hours (AUC(0-4)) were all significantly lower in patients with T315I than those without the mutation (C(2h), 22.3 ng/mL vs. 111.6 ng/mL, P = 0.0242; C(max), 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC(0-4), 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, respectively).",Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587422/),[ng] / [ml],22.3,270543,DB01254,Dasatinib
,22587422,C(2h),"The median plasma concentration at 2 hours (C(2h)), the median plasma maximum concentration (C(max)), and the median area under the observed plasma concentration-time curve from 0 to 4 hours (AUC(0-4)) were all significantly lower in patients with T315I than those without the mutation (C(2h), 22.3 ng/mL vs. 111.6 ng/mL, P = 0.0242; C(max), 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC(0-4), 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, respectively).",Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587422/),[ng] / [ml],111.6,270544,DB01254,Dasatinib
,22587422,C(max),"The median plasma concentration at 2 hours (C(2h)), the median plasma maximum concentration (C(max)), and the median area under the observed plasma concentration-time curve from 0 to 4 hours (AUC(0-4)) were all significantly lower in patients with T315I than those without the mutation (C(2h), 22.3 ng/mL vs. 111.6 ng/mL, P = 0.0242; C(max), 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC(0-4), 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, respectively).",Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587422/),[ng] / [ml],43.8,270545,DB01254,Dasatinib
,22587422,C(max),"The median plasma concentration at 2 hours (C(2h)), the median plasma maximum concentration (C(max)), and the median area under the observed plasma concentration-time curve from 0 to 4 hours (AUC(0-4)) were all significantly lower in patients with T315I than those without the mutation (C(2h), 22.3 ng/mL vs. 111.6 ng/mL, P = 0.0242; C(max), 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC(0-4), 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, respectively).",Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587422/),[ng] / [ml],112.4,270546,DB01254,Dasatinib
,22587422,AUC(0-4),"The median plasma concentration at 2 hours (C(2h)), the median plasma maximum concentration (C(max)), and the median area under the observed plasma concentration-time curve from 0 to 4 hours (AUC(0-4)) were all significantly lower in patients with T315I than those without the mutation (C(2h), 22.3 ng/mL vs. 111.6 ng/mL, P = 0.0242; C(max), 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC(0-4), 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, respectively).",Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587422/),[h·ng] / [ml],108.3,270547,DB01254,Dasatinib
,22587422,AUC(0-4),"The median plasma concentration at 2 hours (C(2h)), the median plasma maximum concentration (C(max)), and the median area under the observed plasma concentration-time curve from 0 to 4 hours (AUC(0-4)) were all significantly lower in patients with T315I than those without the mutation (C(2h), 22.3 ng/mL vs. 111.6 ng/mL, P = 0.0242; C(max), 43.8 ng/mL vs. 112.4 ng/mL, P = 0.0242; AUC(0-4), 108.3 ng·h/mL vs. 268.3 ng·h/mL, P = 0.0061, respectively).",Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587422/),[h·ng] / [ml],268.3,270548,DB01254,Dasatinib
